Filtered By:
Therapy: Statin Therapy
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 11975 results found since Jan 2013.
The Potential Impact of Statins in the Treatment of Patients with COVID-19 Infection
CONCLUSION: Patients with SARS-CoV-2 infection have a high risk of cardiovascular and thrombotic complications and pleiotropic effects of statins may help manage the COVID-19. There is growing evidence that supports the need for trials of statin treatment in COVID-19 infection.PMID:35132599 | DOI:10.1007/978-3-030-85109-5_9
Source: Atherosclerosis - February 8, 2022 Category: Cardiology Authors: Reza Jafarzadeh Esfehani Mohammad Vojdanparast Saman Soleimanpour Gordon A Ferns Amir Avan Source Type: research
Perioperative statin therapy for improving outcomes during and after noncardiac vascular surgery.
CONCLUSIONS: Evidence was insufficient to allow review authors to conclude that statin use resulted in either a reduction or an increase in any of the outcomes examined. The existing body of evidence leaves questions about the benefits of perioperative use of statins for vascular surgery unanswered. Widespread use of statins in the target population means that it may now be difficult for researchers to undertake the large RCTs needed to demonstrate any effect on the incidence of postoperative cardiovascular events. However, participant-reported outcomes have been neglected and warrant further study.
PMID: 23824754 [Pu...
Source: Cochrane Database of Systematic Reviews - July 3, 2013 Category: Journals (General) Authors: Sanders RD, Nicholson A, Lewis SR, Smith AF, Alderson P Tags: Cochrane Database Syst Rev Source Type: research
HMG CoA reductase inhibitors (statins) for dialysis patients.
CONCLUSIONS: Statins have little or no beneficial effects on mortality or cardiovascular events and uncertain adverse effects in adults treated with dialysis despite clinically relevant reductions in serum cholesterol levels.
PMID: 24022428 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - September 11, 2013 Category: Journals (General) Authors: Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Nigwekar SU, Hegbrant J, Strippoli GF Tags: Cochrane Database Syst Rev Source Type: research
Lipid-lowering agents for nephrotic syndrome.
CONCLUSIONS: None of the included studies reported patient-centred outcomes including all-cause mortality, cardiovascular mortality, or non-fatal myocardial infarction; only single studies reported cholesterol (HDL, LDL and total cholesterol), triglycerides, serum creatinine, blood urea nitrogen, liver enzymes, and protein (serum, urine). High quality RCTs need to be conducted to assess the safety and efficacy of lipid-lowering drugs for people with nephrotic syndrome.
PMID: 24327265 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - December 10, 2013 Category: Journals (General) Authors: Kong X, Yuan H, Fan J, Li Z, Wu T, Jiang L Tags: Cochrane Database Syst Rev Source Type: research
HMG CoA reductase inhibitors (statins) for kidney transplant recipients.
CONCLUSIONS: Statins may reduce cardiovascular events in kidney transplant recipients, although treatment effects are imprecise. Statin treatment has uncertain effects on overall mortality, stroke, kidney function, and toxicity outcomes in kidney transplant recipients. Additional studies would improve our confidence in the treatment benefits and harms of statins on cardiovascular events in this clinical setting.
PMID: 24470059 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - February 3, 2014 Category: Journals (General) Authors: Palmer SC, Navaneethan SD, Craig JC, Perkovic V, Johnson DW, Nigwekar SU, Hegbrant J, Strippoli GF Tags: Cochrane Database Syst Rev Source Type: research
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
CONCLUSIONS: Statins consistently lower death and major cardiovascular events by 20% in people with CKD not requiring dialysis. Statin-related effects on stroke and kidney function were found to be uncertain and adverse effects of treatment are incompletely understood. Statins have an important role in primary prevention of cardiovascular events and mortality in people who have CKD.
PMID: 24880031 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - June 3, 2014 Category: Journals (General) Authors: Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Hegbrant J, Strippoli GF Tags: Cochrane Database Syst Rev Source Type: research
HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass.
CONCLUSIONS: Analysis of currently available data did not suggest that preoperative statin use is associated with decreased incidence of AKI in adults after surgery who required cardiac bypass. Although a significant reduction in SCr was seen postoperatively in people treated with statins, this result was driven by results from a single study, where SCr was considered as a secondary outcome. The results of the meta-analysis should be interpreted with caution; few studies were included in subgroup analyses, and significant differences in methodology exist among the included studies. Large high quality RCTs are required to e...
Source: Cochrane Database of Systematic Reviews - March 11, 2015 Category: Journals (General) Authors: Lewicki M, Ng I, Schneider AG Tags: Cochrane Database Syst Rev Source Type: research
Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: Results from the SEARCH database
ConclusionIn this retrospective cohort of men undergoing RP, postoperative statin use was significantly associated with reduced risk of BCR.Whether the association between postoperative statin use and BCR differs by race requires further study.Given these findings, coupled with other studies suggesting that statins may reduce risk of advanced PC, randomized controlled trials are warranted to formally test the hypothesis that statins slow PC progression.
Source: BJU International - March 3, 2014 Category: Urology & Nephrology Authors: Emma H. Allott, Lauren E. Howard, Matthew R. Cooperberg, Christopher J. Kane, William J. Aronson, Martha K. Terris, Christopher L. Amling, Stephen J. Freedland Tags: Urological Oncology Source Type: research
Cardiovascular Risk Management and Hepatitis C: Combining Drugs
AbstractDirect-acting antivirals (DAAs) are known victims (substrate) and perpetrators (cause) of drug –drug interactions (DDIs). These DAAs are used for the treatment of hepatitis C virus (HCV) infections and are highly effective drugs. Drugs used for cardiovascular risk management are frequently used by HCV-infected patients, whom also are treated with DAAs. Therefore, the aim of this review was to describe DDIs between cardiovascular drugs (CVDs) and DAAs. An extensive literature search was performed containing search terms for the marketed DAAs and CVDs (β-blocking agents, ACE inhibitors, angiotensin II antagonists,...
Source: Clinical Pharmacokinetics - September 27, 2018 Category: Drugs & Pharmacology Source Type: research
In search of the optimal setting for statin trials in prostate cancer: the power of population-based studies
Prostate Cancer and Prostatic Diseases, Published online: 29 March 2021; doi:10.1038/s41391-021-00355-yIn search of the optimal setting for statin trials in prostate cancer: the power of population-based studies
Source: Prostate Cancer and Prostatic Diseases - March 29, 2021 Category: Urology & Nephrology Authors: Emma H. Allott Emma L. Craig Konrad H. Stopsack Source Type: research
